Literature DB >> 2517867

The immune-dependence of chemotherapy in experimental schistosomiasis.

M J Doenhoff1.   

Abstract

Experimental evidence indicates that immune effector mechanisms can enhance the activity of schistosomicidal drugs. Praziquantel, oxamniquine, hycanthone and antimony were less effective against Schistosoma mansoni infections in mice immunosuppressed by T cell-deprivation, than against comparable infections in normal mice. The schistosomicidal activities of praziquantel, oxamniquine and antimony have been experimentally enhanced by the synergistic action of immune sera. In passive serum transfer experiments a S. mansoni antigen of Mr 27kD with non-specific esterase activity was identified as a potentially sensitive target for the antibodies that interact with praziquantel. Indirect immunofluorescence indicated that this antigen was exposed on the worm surface as a result of praziquantel treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2517867     DOI: 10.1590/s0074-02761989000500004

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  10 in total

1.  Activity of artemether and mefloquine against juvenile and adult Schistosoma mansoni in athymic and immunocompetent NMRI mice.

Authors:  Jennifer Keiser; Mireille Vargas; Michael J Doenhoff
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

Review 2.  Mefloquine, a new type of compound against schistosomes and other helminthes in experimental studies.

Authors:  Shu-hua Xiao
Journal:  Parasitol Res       Date:  2013-08-27       Impact factor: 2.289

3.  Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of defined worm surface antigens.

Authors:  Marwa H El-Faham; Maha M Eissa; Joseph E Igetei; Eglal I Amer; Susan Liddell; Mervat Z El-Azzouni; Michael J Doenhoff
Journal:  PLoS Negl Trop Dis       Date:  2017-08-25

Review 4.  Pharmacological and immunological effects of praziquantel against Schistosoma japonicum: a scoping review of experimental studies.

Authors:  Shu-Hua Xiao; Jun Sun; Ming-Gang Chen
Journal:  Infect Dis Poverty       Date:  2018-02-07       Impact factor: 4.520

5.  Prevalence and intensity of Schistosoma mansoni infection in pediatric populations on antiretroviral therapy in north-western Tanzania: a cross-sectional study.

Authors:  Humphrey D Mazigo; Laurence Kirway; Emmanuela Ausebio Ambrose
Journal:  BMJ Open       Date:  2019-07-24       Impact factor: 2.692

6.  Validation of a human-serum-based in vitro growth method for drug screening on juvenile development stages of Schistosoma mansoni.

Authors:  Valentin Buchter; Pierre H H Schneeberger; Jennifer Keiser
Journal:  PLoS Negl Trop Dis       Date:  2021-03-30

7.  Fluorescence/luminescence-based markers for the assessment of Schistosoma mansoni schistosomula drug assays.

Authors:  Gordana Panic; Dayana Flores; Katrin Ingram-Sieber; Jennifer Keiser
Journal:  Parasit Vectors       Date:  2015-12-08       Impact factor: 3.876

8.  Epidemiology and interactions of Human Immunodeficiency Virus - 1 and Schistosoma mansoni in sub-Saharan Africa.

Authors:  Humphrey D Mazigo; Fred Nuwaha; Shona Wilson; Safari M Kinung'hi; Domenica Morona; Rebecca Waihenya; Jorg Heukelbach; David W Dunne
Journal:  Infect Dis Poverty       Date:  2013-01-24       Impact factor: 4.520

9.  Immune Dysfunction and Coinfection with Human Immunodeficiency Virus and Schistosoma japonicum in Yi People.

Authors:  Yu Yang; Peng-Lei Xiao; Ya Yang; Jian-Chuan Gao; Yan Shi; Wan-Ting Cheng; Yue Chen; Xiu-Xia Song; Qing-Wu Jiang; Yi-Biao Zhou
Journal:  J Immunol Res       Date:  2018-07-02       Impact factor: 4.818

10.  Immunohistochemical Investigations of Treatment with Ro 13-3978, Praziquantel, Oxamniquine, and Mefloquine in Schistosoma mansoni-Infected Mice.

Authors:  Gordana Panic; Marie-Thérèse Ruf; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.